Lawrence Otto Klein Sells 1,729 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the transaction, the chief executive officer owned 925,580 shares in the company, valued at $64,503,670.20. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oruka Therapeutics Trading Down 1.7%

Shares of ORKA opened at $67.71 on Wednesday. The firm’s 50-day moving average is $64.00 and its two-hundred day moving average is $44.58. Oruka Therapeutics, Inc. has a twelve month low of $10.77 and a twelve month high of $91.00. The firm has a market capitalization of $4.08 billion, a P/E ratio of -34.90 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.04. Analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Fairmount Funds Management LLC boosted its position in Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after acquiring an additional 333,340 shares during the last quarter. Viking Global Investors LP acquired a new stake in Oruka Therapeutics during the third quarter worth approximately $51,280,000. Deep Track Capital LP boosted its position in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after acquiring an additional 735,983 shares during the last quarter. Vanguard Group Inc. boosted its position in Oruka Therapeutics by 38.1% during the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock worth $74,366,000 after acquiring an additional 676,865 shares during the last quarter. Finally, RTW Investments LP boosted its position in Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after acquiring an additional 112,499 shares during the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on ORKA shares. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Piper Sandler restated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the company a “buy” rating in a research report on Monday, April 27th. UBS Group increased their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Finally, BTIG Research reiterated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research report on Thursday, May 14th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $131.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.